肝细胞生长因子受体c-met在骨肉瘤中的表达及其临床意义  

Expression of C-met and the clinical significance and prognostic value in osteosarcoma

作　　者：刘云燕[1] 纪振钢[1] 杨连甲[1] 文艳华[1] 裘秀春[1] 张殿忠[1] 马琼[1] 许啸[1] 范清宇[1] 

机构地区：[1]第四军医大学唐都医院全军骨肿瘤研究所,陕西西安710038

出　　处：《现代肿瘤医学》2010年第2期361-363,共3页Journal of Modern Oncology

摘　　要：目的:探讨骨肉瘤组织中肝细胞生长因子受体c-met蛋白的表达情况,分析其临床意义及与预后的关系。方法:应用免疫组织化学方法检测行手术的35例骨肉瘤及13例骨样骨瘤患者标本肝细胞生长因子受体c-met的表达,并分析其与临床因素和预后的关系。结果:骨肉瘤组织中肝细胞生长因子受体c-met的阳性表达率为80%(28/35),而在骨样骨瘤中的表达率为7.7%(1/12),两者比较显著差异(P<0.01);结合临床资料分析,其表达与患者性别、年龄、发病次数、肿瘤体积、病理分型无关(P>0.05),而与临床分期、有无转移有关(P<0.05)。结论:C-met可能在骨肉瘤细胞侵袭、转移的过程中起重要作用;肝细胞生长因子受体c-met可以作为骨肉瘤诊断和预测转移的指标。Objective：To observe the expression of c -met in osteosarcoma, and investigate its clinical significance and prognostic value. Methods：The integrated clinical data were retrospectively analyzed of 35 osteosarcoma and 13 osteoidoseoma patients who were undergone radical operation, and the paraffin -embedded tissues of the chardoma samples were collected. The expression of hepatocyte growth factor receptor c - met was detected with immuno- histochemical technique. The relationships between c - met and clinical variables were analyzed. Results： The positive expression rate of c - met in 35 patients with osteosarcoma was 80% （ 28/35 ）, and significantly higher than that in the patients with osteoidosteoma （7.7% , P 〈 0.01 ）. In 30 patients, a negative correlation was found between the expression of c - met and sex, age, time, tumor size, as well as pathology types, without statistical significance （ P 〉 0.05 ）, but there was a positive correlation with clinical stages and the metastasis of osteosarcoma （P 〈 0.05）. Conclusion： The abnormal expression of c - met is an important adverse prognostic factor for survival in osteosarcom patients. c- met may be marker of diagnosis and prognosis in osteosarcoma.

关 键 词：肝细胞生长因子受体c—met 骨肉瘤 浸润 转移 

分 类 号：R730.3[医药卫生—肿瘤]